1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014

Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014" provides data on the Community-Acquired Bacterial Pneumonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Community-Acquired Bacterial Pneumonia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Community-Acquired Bacterial Pneumonia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H2, 2014
Table of Contents

Introduction 6
Community-Acquired Bacterial Pneumonia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Community-Acquired Bacterial Pneumonia 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Community-Acquired Bacterial Pneumonia 31
Sep 25, 2014: Cempra Completes Enrollment of Solitaire-Oral Phase 3 Trial 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Actavis plc 32
Clinical Trial Overview of Actavis plc 32
Cempra, Inc. 33
Clinical Trial Overview of Cempra, Inc. 33
Pfizer Inc. 34
Clinical Trial Overview of Pfizer Inc. 34
Cempra Pharmaceuticals, Inc. 35
Clinical Trial Overview of Cempra Pharmaceuticals, Inc. 35
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
Nabriva Therapeutics AG 37
Clinical Trial Overview of Nabriva Therapeutics AG 37
Cubist Pharmaceuticals, Inc. 38
Clinical Trial Overview of Cubist Pharmaceuticals, Inc. 38
Boehringer Ingelheim Auslandsbeteiligungs GmbH 39
Clinical Trial Overview of Boehringer Ingelheim Auslandsbeteiligungs GmbH 39
Bayer AG 40
Clinical Trial Overview of Bayer AG 40
Basilea Pharmaceutica AG 41
Clinical Trial Overview of Basilea Pharmaceutica AG 41
Clinical Trial Overview of Top Institutes / Government 42
Yokohama Rosai Hospital 42
Clinical Trial Overview of Yokohama Rosai Hospital 42
Nagasaki Evaluation Organization for Clinical Interventions 43
Clinical Trial Overview of Nagasaki Evaluation Organization for Clinical Interventions 43
Central Japan Lung Study Group 44
Clinical Trial Overview of Central Japan Lung Study Group 44
Albany Medical Center 45
Clinical Trial Overview of Albany Medical Center 45
Five Key Clinical Profiles 46
Appendix 109
Abbreviations 109
Definitions 109
Research Methodology 110
Secondary Research 110
About GlobalData 111
Contact Us 111
Disclaimer 111
Source 111

List of Tables

Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Community-Acquired Bacterial Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Actavis plc, 2014* 32
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Cempra, Inc., 2014* 33
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 34
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Cempra Pharmaceuticals, Inc., 2014* 35
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Nabriva Therapeutics AG, 2014* 37
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Cubist Pharmaceuticals, Inc., 2014* 38
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Boehringer Ingelheim Auslandsbeteiligungs GmbH, 2014* 39
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 40
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Basilea Pharmaceutica AG, 2014* 41
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Yokohama Rosai Hospital, 2014* 42
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Nagasaki Evaluation Organization for Clinical Interventions, 2014* 43
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Central Japan Lung Study Group, 2014* 44
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials Market, Global, Clinical Trials by Albany Medical Center, 2014* 45

List of Figures

Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Community-Acquired Bacterial Pneumonia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Community-Acquired Bacterial Pneumonia to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Community-Acquired Bacterial Pneumonia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Community-Acquired Bacterial Pneumonia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Community-Acquired Bacterial Pneumonia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Community-Acquired Bacterial Pneumonia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 110

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global animal antibiotics and antimicrobials market is estimated to grow at a CAGR of 4.6% from 2016 to 2021, to reach USD 4.73 billion by 2021 from USD 3.77 billion in 2016. The growth of this market ...

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

  • $ 4995
  • Industry report
  • January 2017
  • by GBI Research

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance Summary The antibacterial drug market covers ...

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the ...

Acetic Acid Markets In China

January 2017 $ 4000

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.